Head to Head Study of Anti-VEGF Treatment.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT02577107
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular age-related macular degeneration

Key Dates

First listed
Oct 16, 2015
Start date
Jan 13, 2016
Status verified
Jul 2017
Primary completion
Jul 9, 2016
Completion
Jul 9, 2016

Study Design

Enrollment
12 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Ranibizumab 0.5 mg
    Three monthly injections of 0.5mg Ranibizumab
  • Active Comparator: Conbercept 0.5 mg
    Three monthly injections of 0.5mg Conbercept

Primary Outcome Measure

Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day) [ Time Frame: Baseline, Visit 5 (Day 8 +/- 1 day) ]

Related Studies